Valuation: Intensity Therapeutics, Inc.

Market Cap 12.3M 10.79M 10.05M 9.24M 17.33M 1.17B 17.63M 119M 46.67M 583M 46.17M 45.17M 2.01B P/E 2026 *
-1.24x
P/E 2027 * -1.36x
Enterprise Value 12.3M 10.79M 10.05M 9.24M 17.33M 1.17B 17.63M 119M 46.67M 583M 46.17M 45.17M 2.01B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
95.45%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Intensity Therapeutics, Inc.

1 day-0.44%
1 week+3.41%
Current month+10.98%
1 month+10.98%
3 months-11.99%
6 months-52.34%
Current year-55.63%
1 week 4.31
Extreme 4.31
4.57
1 month 3.93
Extreme 3.93
5
Current year 3.51
Extreme 3.51
11.07
1 year 3.51
Extreme 3.51
43.5
3 years 3.51
Extreme 3.51
286
5 years 3.51
Extreme 3.51
286
10 years 3.51
Extreme 3.51
286
Manager TitleAgeSince
Chief Executive Officer 67 2012-03-31
Director of Finance/CFO 57 2023-12-10
Corporate Officer/Principal - 2023-08-31
Director TitleAgeSince
Chairman 67 2012-03-31
Director/Board Member 60 2016-05-31
Director/Board Member 66 2018-04-30
Date Insider Type Main position Quantity % Market Cap.
7/16/26 Free

Chief Executive Officer

78,000 2.8859%
7/16/26 Free

Director

5,500 0.2035%
7/16/26 Free

Chief Financial Officer

34,000 1.2579%
Change 5-day change 1-year change 3-year change Capi.($)
-0.44%+3.41%-46.15%-96.81% 12.3M
+0.14%-0.67%-0.88%+11.02% 47.88B
-2.24%+0.31%+393.45%+615.13% 39.09B
+1.40%+3.69%+12.21%+46.79% 36.75B
+13.94%+20.49%+22.85%+7.42% 40.55B
-0.73%+3.38%+4.94%+41.45% 27.96B
+0.40%-0.30% - - 16.77B
-3.12%+7.39%+26.03%+124.08% 15.94B
+2.39%-1.64%+4.74%+9.95% 13.55B
+6.79%+8.17%-4.97%-28.52% 13.81B
Average +1.85%+4.51%+45.80%+81.17% 25.23B
Weighted average by Cap. +2.37%+5.03%+73.28%+125.12%

Financials

2026 *2027 *
Net sales - -
Net income -10.9M -9.57M -8.91M -8.19M -15.36M -1.04B -15.62M -106M -41.37M -516M -40.92M -40.04M -1.78B -13.3M -11.67M -10.87M -10M -18.74M -1.27B -19.06M -129M -50.47M -630M -49.93M -48.85M -2.18B
Net Debt - -
Logo Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.
Employees
6
Date Price Change Volume
26-07-28 US$4.550 -0.44% 30,005
26-07-27 US$4.570 +2.70% 10,771
26-07-24 US$4.450 +0.45% 3,460
26-07-23 US$4.430 +0.91% 7,827
26-07-22 US$4.390 -0.23% 4,835
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.550USD
Average target price
24.80USD
Spread / Average Target
+445.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INTS Stock